On 12/28/23, Neogenomics Inc (NASDAQ: NEO) stock suffered a major decline of -18.1%, closing at $16.79. Moreover, exceptionally high trading volume at 425% of normal accompanied the decline. The stock has been strong relative to the market over the last nine months but has declined -16.1% during the last week.
Current PriceTarget Research Rating
NEO is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Neogenomics has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Neogenomics has a very low Appreciation Score of 11 but a slightly positive Power Rating of 68, triggering the Negative Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment